Nurexone Biologic Stock Working Capital
| NRX Stock | 0.71 0.01 1.43% |
NurExone Biologic fundamentals help investors to digest information that contributes to NurExone Biologic's financial success or failures. It also enables traders to predict the movement of NurExone Stock. The fundamental analysis module provides a way to measure NurExone Biologic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NurExone Biologic stock.
Net Working Capital is likely to drop to about 70.3 K in 2024. Change In Working Capital is likely to drop to 3,800 in 2024. NurExone |
NurExone Biologic Company Working Capital Analysis
NurExone Biologic's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current NurExone Biologic Working Capital | 74 K |
Most of NurExone Biologic's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NurExone Biologic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
NurExone Capital Lease Obligations
Capital Lease Obligations |
|
Based on the company's disclosures, NurExone Biologic has a Working Capital of 74 K. This is 99.98% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The working capital for all Canada stocks is 99.99% higher than that of the company.
NurExone Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NurExone Biologic's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NurExone Biologic could also be used in its relative valuation, which is a method of valuing NurExone Biologic by comparing valuation metrics of similar companies.NurExone Biologic is currently under evaluation in working capital category among its peers.
NurExone Fundamentals
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 46.99 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 4.75 % | ||||
| Number Of Shares Shorted | 32.31 K | ||||
| Price To Book | 13.94 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Target Price | 4.03 | ||||
| Beta | -0.091 | ||||
| Market Capitalization | 50.3 M | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | 74 K | ||||
| Net Asset | 2.17 M |
About NurExone Biologic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NurExone Biologic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NurExone Biologic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NurExone Biologic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.